With a median follow-up of 50 months ( IQR 38-61 ) , disease-free survival at 3 years was 759 % ( 95 % CI 724-795 ) in the investigational group and 712 % ( 95 % CI 676-749 ) in the control group ( hazard ratio [ HR ] 079 , 95 % CI 064-098 ; p = 003 ) .